H.C. Wainwright lowered the firm’s price target on Bicycle Therapeutics (BCYC) to $33 from $55 and keeps a Buy rating on the shares afar the company data from the ongoing Phase 1/2 Duravelo-1 study evaluating the combination of zelenectide pevedotin and pembrolizumab in first-line metastatic urothelial cancer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCYC:
- Bicycle Therapeutics price target lowered to $17 from $28 at B. Riley
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
- Cantor Fitzgerald biotech analyst holds an analyst/industry conference call
- Molson Coors upgraded, Rivian downgraded: Wall Street’s top analyst calls
- Bicycle Therapeutics initiated with an Equal Weight at Stephens